DK3653709T3 - Fremgangsmåder til modulering af dna-reparationsresultater - Google Patents
Fremgangsmåder til modulering af dna-reparationsresultater Download PDFInfo
- Publication number
- DK3653709T3 DK3653709T3 DK19192206.1T DK19192206T DK3653709T3 DK 3653709 T3 DK3653709 T3 DK 3653709T3 DK 19192206 T DK19192206 T DK 19192206T DK 3653709 T3 DK3653709 T3 DK 3653709T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- dna repair
- repair results
- modulating dna
- modulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298129P | 2016-02-22 | 2016-02-22 | |
| US201662344876P | 2016-06-02 | 2016-06-02 | |
| EP17711029.3A EP3420080B1 (en) | 2016-02-22 | 2017-02-21 | Methods for modulating dna repair outcomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3653709T3 true DK3653709T3 (da) | 2021-03-08 |
Family
ID=58314500
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17711029T DK3420080T3 (da) | 2016-02-22 | 2017-02-21 | Fremgangsmåde til modulering af dna-repair-resultater |
| DK19192206.1T DK3653709T3 (da) | 2016-02-22 | 2017-02-21 | Fremgangsmåder til modulering af dna-reparationsresultater |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17711029T DK3420080T3 (da) | 2016-02-22 | 2017-02-21 | Fremgangsmåde til modulering af dna-repair-resultater |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11155814B2 (da) |
| EP (2) | EP3420080B1 (da) |
| DK (2) | DK3420080T3 (da) |
| ES (2) | ES2847252T3 (da) |
| WO (1) | WO2017147056A1 (da) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11680268B2 (en) | 2014-11-07 | 2023-06-20 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
| AU2016326711B2 (en) | 2015-09-24 | 2022-11-03 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/Cas-mediated genome editing |
| EP3433363A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| US11427838B2 (en) | 2016-06-29 | 2022-08-30 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders |
| AU2017306676B2 (en) | 2016-08-03 | 2024-02-22 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| KR20190130613A (ko) | 2017-03-23 | 2019-11-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US20220238182A1 (en) * | 2017-12-15 | 2022-07-28 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019118948A2 (en) * | 2017-12-15 | 2019-06-20 | Massachusetts Institute Of Technology | Systems and methods for predicting repair outcomes in genetic engineering |
| CA3087715A1 (en) | 2018-02-08 | 2019-08-15 | Zymergen Inc. | Genome editing using crispr in corynebacterium |
| US20210123072A1 (en) * | 2018-04-20 | 2021-04-29 | Dana-Farber Cancer Institute, Inc. | Multifunctional nucleic acid reporter constructs |
| US20210230568A1 (en) * | 2018-05-04 | 2021-07-29 | University Of Massachusetts | Microhomology mediated repair of microduplication gene mutations |
| WO2019224603A1 (en) * | 2018-05-24 | 2019-11-28 | Crispr Therapeutics Ag | Methods and compositions for efficient gene deletion |
| EP3942040A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| EP3966323A4 (en) * | 2019-05-06 | 2024-04-24 | The Regents Of The University Of Michigan | TARGETED THERAPY |
| GB201909439D0 (en) * | 2019-07-01 | 2019-08-14 | Artios Pharma Ltd | Novel construct |
| EP4022057A1 (en) * | 2019-08-27 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of disorders associated with repetitive dna |
| US11530425B2 (en) | 2019-10-09 | 2022-12-20 | Massachusetts Institute Of Technology | Systems, methods, and compositions for correction of frameshift mutations |
| GB202003814D0 (en) * | 2020-03-16 | 2020-04-29 | Cancer Research Tech Ltd | Optimised methods for cleavage of target sequences |
| MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
| EP4298221A1 (en) * | 2021-02-26 | 2024-01-03 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9 |
| WO2022182957A1 (en) * | 2021-02-26 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9 |
| WO2023078347A1 (zh) * | 2021-11-03 | 2023-05-11 | 南京金斯瑞生物科技有限公司 | 检测环境中sgRNA的残留量的引物、试剂盒及方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6569681B1 (en) * | 2000-03-14 | 2003-05-27 | Transkaryotic Therapies, Inc. | Methods of improving homologous recombination |
| AU2001256530A1 (en) * | 2000-05-20 | 2001-12-03 | Cancer Research Technology Limited | Drug screening systems and assays |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| WO2007013979A2 (en) * | 2005-07-20 | 2007-02-01 | Invitrogen Corporation | Methods for increasing efficiency of homologous recombination |
| SG178940A1 (en) | 2009-09-18 | 2012-04-27 | Selexis Sa | Products and methods for enhanced transgene expression and processing |
| WO2011078662A1 (en) * | 2009-12-21 | 2011-06-30 | Keygene N.V. | Dsrna for improved genetic modification of plant dna |
| WO2012168307A2 (en) * | 2011-06-07 | 2012-12-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Improved recombination efficiency by inhibition of nhej dna repair |
| PT2800811T (pt) | 2012-05-25 | 2017-08-17 | Univ California | Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição |
| ES2901396T3 (es) * | 2013-03-14 | 2022-03-22 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| WO2014172458A1 (en) * | 2013-04-16 | 2014-10-23 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
| US9163284B2 (en) * | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| EP3186376B1 (en) * | 2014-08-27 | 2019-03-20 | Caribou Biosciences, Inc. | Methods for increasing cas9-mediated engineering efficiency |
| US11680268B2 (en) * | 2014-11-07 | 2023-06-20 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
| US10059940B2 (en) * | 2015-01-27 | 2018-08-28 | Minghong Zhong | Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents |
| AU2016263026A1 (en) * | 2015-05-15 | 2017-11-09 | Pioneer Hi-Bred International, Inc. | Guide RNA/Cas endonuclease systems |
| ES2929047T3 (es) * | 2016-06-24 | 2022-11-24 | Scripps Research Inst | Transportador de nucleósido trifosfato novedoso y usos del mismo |
-
2017
- 2017-02-21 ES ES19192206T patent/ES2847252T3/es active Active
- 2017-02-21 ES ES17711029T patent/ES2754785T3/es active Active
- 2017-02-21 EP EP17711029.3A patent/EP3420080B1/en active Active
- 2017-02-21 WO PCT/US2017/018679 patent/WO2017147056A1/en active Application Filing
- 2017-02-21 DK DK17711029T patent/DK3420080T3/da active
- 2017-02-21 DK DK19192206.1T patent/DK3653709T3/da active
- 2017-02-21 US US16/078,014 patent/US11155814B2/en active Active
- 2017-02-21 EP EP19192206.1A patent/EP3653709B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3420080T3 (da) | 2019-11-25 |
| WO2017147056A1 (en) | 2017-08-31 |
| ES2754785T3 (es) | 2020-04-20 |
| EP3653709A1 (en) | 2020-05-20 |
| US20190055549A1 (en) | 2019-02-21 |
| EP3653709B1 (en) | 2020-12-09 |
| ES2847252T3 (es) | 2021-08-02 |
| US11155814B2 (en) | 2021-10-26 |
| EP3420080A1 (en) | 2019-01-02 |
| EP3420080B1 (en) | 2019-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3653709T3 (da) | Fremgangsmåder til modulering af dna-reparationsresultater | |
| DK3559265T3 (da) | Fremgangsmåde til behandling af polynukleotider | |
| DK3448990T3 (da) | Forbedrede fremgangsmåder til modificering af målnukleinsyrer | |
| DK3186376T3 (da) | Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet | |
| DK3497207T3 (da) | Fremgangsmåder til påvisning af aav | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3137605T3 (da) | Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression | |
| DK3283080T3 (da) | Sammensætninger til modulation af c9orf72-ekspression | |
| DK3110988T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
| DK3316703T3 (da) | Fremgangsmåde til forbedring af dyrs ydeevne | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3707723T3 (da) | Teknikker til indeksering af nukleinsyrer | |
| DK3122444T3 (da) | Fremgangsmåde til fremstilling af membraner | |
| DK3344805T3 (da) | Fremgangsmåde til udvælgelse af aptamerer til ubundne mål | |
| DK3201361T3 (da) | Fremgangsmåder til kvantificering af cellefrit DNA | |
| DK3359281T3 (da) | Fremgangsmåde til udtrækning af CO2 | |
| DK3314010T3 (da) | Fremgangsmåde til detektering af kromosomaberrationer | |
| DK3728585T3 (da) | Hidtil ukendte fremgangsmåder til fremstilling af oligonukleotider | |
| DK3520591T3 (da) | Fremgangsmåde til spredning af gødningsmidler | |
| DK3393468T3 (da) | Fremgangsmåder til behandling af en immundefektsygdom | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| DK3534709T3 (da) | Substituerede sulfonylamider til bekæmpelse af skadedyr | |
| DK3408015T3 (da) | Fremgangsmåde til fremstilling af emulsioner | |
| DK3164716T3 (da) | Fremgangsmåde til diagnosticering af neurodegenerative sygdomme |